We advised:
- Affimed's underwriters in connection with its IPO on NASDAQ.
- argenx's underwriters in connection with its IPO on NASDAQ and various consecutive capital raises since its IPO in 2017;
- argenx and Merus in their follow-on offerings and Centogene on its Nasdaq IPO, raising a total of up to USD 627.6 million for these companies within 48 hours.
- Agendi N.V.'s underwriters in connection with its proposed IPO on Euronext Amsterdam (postponed shortly before pricing).
- Azalea Vision with its Series A financing round.
- Centogene in its Nasdaq IPO
- InflaRx on its listing on NASDAQ.
- Investor syndicate on the Series A investment in Dualyx.
- KBC securities (underwriter) in connection with the public rights offering by Biocartis.
- Kiadis Pharma N.V.'s underwriters in connection with its IPO and the listing of its shares on Euronext's Amsterdam and Brussels exchanges.
- Merus' shareholders counsel on Merus' IPO.
- Morrow on its Series B financing round.
- Mylan tender offer for Meda.
- Nyxoah on its Nasdaq listing and private placement (approx. USD 98 million) in 2021 following its IPO on Euronext Brussels (approx. EUR 85 million) in 2020.
- Nyxoah on its USD 50 million at-the-market offering (ATM) program and filing of a registration statement.
- Nyxoah on a USD 15 million private placement of new shares and on a USD 3 million sale of new shares under its ATM program.
- Onward Medical on its IPO on Euronext Brussels and Euronext Amsterdam
- Pharvaris on various investment rounds and its listing on NASDAQ.
- ProQR Therapeutics in its listing on NASDAQ.
- Qiagen N.V.'s underwriters in connection with the secondary offering and listing of its shares on the Frankfurt Stock Exchange and NASDAQ.
- uniQure N.V.'s underwriters in connection with its IPO on NASDAQ.